mail@shareholdersfoundation.com
An investor in Hemispherx BioPharma, Inc (Public, AMEX:HEB) has filed a lawsuit in the United States District Court for the Eastern District of Pennsylvania on behalf of those who purchased the securities of Hemispherx Biopharma, Inc. (AMEX:
If you purchased the securities of Hemispherx Biopharma, Inc. (AMEX: HEB) between February 18, 2009 and October 30, 2009, you have certain options and there are strict and short deadlines running. Deadline: January 11, 2010. Those HEB shareholders and current long term HEB investors should contact the Shareholders Foundation, Inc. at:
Email: mail@shareholdersfoundation.com or at: +1 (858) 779 – 1554
According to the complaint the plaintiff alleges that the defendants violated the federal securities laws by misleading investors regarding the status of Hemispherx's New Drug Application ("NDA") for its drug Ampligen with the U.S. Food and Drug Administration ("FDA"). Specifically, so the lawsuit, defendants failed to disclose that the FDA had requested several reports from Hemispherx Biopharma before the NDA could even be considered, thus delaying the possible approval of Ampligen by several months at a minimum. Then, on November 2, 2009, when Hemispherx Biopharma disclosed this information, the price of Hemispherx Biopharma securities (HEB) fell 20% to close at $1.13 on the next trading day, November 3, 2009.
Hemispherx BioPharma, Inc said in a press release that it believes that the lawsuit is without merit and the fraud claim is irrefutably false.
Hemispherx Biopharma, Inc., located inPhiladelphia, PA, is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s products include Ampligen and Alferon N and Injection. Hemispherx BioPharma, Inc reported in 2007 Total Revenue of $1.06million and in 2008 Total Revenue of $0.27million. Shares of Hemispherx BioPharma, Inc traded recently at $1.08 per share.
Those who purchased the securities of Hemispherx Biopharma, Inc. (AMEX: HEB) between February 18, 2009 and October 30, 2009, have certain options and there are strict and short deadlines running. Deadline: January 11, 2010. Those HEB shareholders and current long term HEB investors should contact the Shareholders Foundation, Inc. at:
Email: mail@shareholdersfoundation.com or at: +1 (858) 779 – 1554
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423 -
92108 San Diego
Tel:+1-(858)-
Fax:+1-(858)-
mail@shareholdersfoundation.com
www.ShareholdersFoundation.com
____________________________________________________________
Photo:
http://www.prlog.org/
